Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-09-07

FDA Approved: COPAXONE — Supplemental Application (Teva Neuroscience, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Copaxone (glatiramer acetate) from Teva Neuroscience, Inc., indicating an update to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • COPAXONE (GLATIRAMER ACETATE)

Snippet

SUPPL AP for COPAXONE (GLATIRAMER ACETATE)